The NORAD knockdown reduces hypoxia-induced VM formation, 5-FU resistance, and HIF-1α-mediated EMT by ponging miR-495-3p, suggesting NORAD as a potential therapeutic target for CRC [60]. The gene discussed is NORAD; the disease is colorectal carcinoma.